Drug Information
Drug General Information | Top | |||
---|---|---|---|---|
Drug ID |
D8J3SW
|
|||
Drug Name |
GLY-200
|
|||
Indication | Type 2 diabetes [ICD-11: 5A11; ICD-10: E08-E13] | Phase 2 | [1] | |
Company |
Glyscend Therapeutics Lowell, MA
|
References | Top | |||
---|---|---|---|---|
REF 1 | ClinicalTrials.gov (NCT05478525) A Phase 2 Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety, Tolerability, and Pharmacodynamic Effects of GLY-200 in Type 2 Diabetic Patients. U.S.National Institutes of Health. |
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.